|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 6
2017
Harbeck, N.; Nitz, U. A.; Matthias, C.; Kates, R.; Braun, M.; Kümmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Grischke, E.-M.; Haas, S. L. de; Deurloo, R.; Schumacher, J.; Würstlein, R.; Kreipe, H. H. und Gluz, O.
(2017):
The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC).
In: Cancer Research, Bd. 77
2016
Liedtke, C.; Gluz, O.; Heinisch, F.; Feuerhake, F.; Kreipe, H. H.; Clemens, M.; Nuding, B.; Kraemer, S.; Reimer, T.; Svedman, C.; Shak, S.; Nitz, U.; Kates, R. E.; Harbeck, N. und Christgen, M.
(2016):
Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) A translational analysis of the prospective WSG planB trial.
In: Cancer Research, Bd. 76
Harbeck, N.; Gluz, O.; Christgen, M.; Braun, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Haas, S. L. de; Kiermaier, A.; Kreipe, H. H. und Nitz, U.
(2016):
Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer.
In: Cancer Research, Bd. 76
Braun, M.; Gluz, O.; Nitz, U.; Christgen, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Kreipe, H.-H. und Harbecks, N.
(2016):
Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer.
In: Oncology Research and Treatment, Bd. 39: S. 2
Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Kraemer, S.; Nuding, B.; Aktas, B.; Kuemmel, S.; Reimer, T.; Lorenz-Salehi, F.; Krabisch, P.; Just, M.; Augustin, D.; Liedtke, C.; Svedman, C.; Shak, S.; Wuerstlein, R.; Kreipe, H. und Harbeck, N.
(2016):
Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer.
In: European Journal of Cancer, Bd. 57:
S6-S6
2004
Härtl, K. und Kraemer, S.
(2004):
Verhaltenstherapie einer Patientin mit Genitalkarzinom, somatoformer Schmerzstörung und Dyspareunie.
In: Verhaltenstherapie, Nr. 1: S. 52-57
[PDF, 76kB]